biostudies-literatureGealekman ONIDDK NIH HHS2794-2799https://www.ebi.ac.uk/biostudies/studies/S-EPMC3549462biostudies-literatureUnknown55(10)<h4>Aims/hypothesis</h4>Recent reports of decreased capillary density in the adipose tissue of obese individuals suggest that an imbalance of angiogenesis and adipogenesis may, in part, underlie insulin resistance. This study aimed to determine whether the insulin-sensitising peroxisome proliferator-activated receptor γ (PPARγ) activator rosiglitazone affects adipose tissue vascularisation in normal humans.<h4>Methods</h4>A randomised, parallel-group, investigator-blinded placebo-controlled trial was conducted with normoglycaemic volunteers with BMI 27-43, recruited from the community at the University of Massachusetts Medical School, Worcester, MA, USA. Peri-umbilical adipose tissue biopsies were obtained before and after treatment for 6 weeks with rosiglitazone (8 mg once daily) or placeDiabetologiaEffect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial.PMC3549462DK089101DK32520R01 DK089101P30 DK032520Gurav KGusev AMalkani SCorvera SThompson MGealekman OGuseva NHartigan CfalseEffect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial.<h4>Aims/hypothesis</h4>Recent reports of decreased capillary density in the adipose tissue of obese individuals suggest that an imbalance of angiogenesis and adipogenesis may, in part, underlie insulin resistance. This study aimed to determine whether the insulin-sensitising peroxisome proliferator-activated receptor γ (PPARγ) activator rosiglitazone affects adipose tissue vascularisation in normal humans.<h4>Methods</h4>A randomised, parallel-group, investigator-blinded placebo-controlled trial was conducted with normoglycaemic volunteers with BMI 27-43, recruited from the community at the University of Massachusetts Medical School, Worcester, MA, USA. Peri-umbilical adipose tissue biopsies were obtained before and after treatment for 6 weeks with rosiglitazone (8 mg once daily) or place2012-01-01T00:00:00Z2012 Oct2025-04-04T01:06:00.642Z2019-03-27T01:03:32ZS-EPMC35494622284705910.1007/s00125-012-2658-2